Dr. Muhammad Rizvi, MD
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 25
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 330
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
PA license MD449290 -
Internal Medicine Physician
MA license 228139
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- St Lukes Hospital Bethlehem, PA
- Lehigh Valley Hospital Allentown, PA
- Lehigh Valley Hospital - Pocono East Stroudsburg, PA
- Schuylkill Medical Center - South Jackson Street Pottsville, PA
- Lehigh Valley Hospital - Macungie Macungie, PA
Medical groups
- Lehigh Valley Physician Group (2,542 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 330
- Services billed
- 1,054
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 337 | 192 |
| Established patient office or other outpatient visit, 40-54 minutes | 333 | 113 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 57 | 33 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 41 | 41 |
| New patient office or other outpatient visit, 60-74 minutes | 31 | 31 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Anastrozole Other prescribers in Allentown, PA | 200 |
| Letrozole Other prescribers in Allentown, PA | 77 |
| Dexamethasone Other prescribers in Allentown, PA | 74 |
| Tamoxifen Citrate Other prescribers in Allentown, PA | 71 |
| Prochlorperazine Maleate Other prescribers in Allentown, PA | 65 |
| Alendronate Sodium Other prescribers in Allentown, PA | 51 |
| Eliquis (apixaban) Other prescribers in Allentown, PA | 50 |
| Oxycodone Hcl Other prescribers in Allentown, PA | 45 |
| Abiraterone Acetate | 41 |
| Levothyroxine Sodium Other prescribers in Allentown, PA | 31 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 1 payments worth $479 in total to this clinician.
| E.r. Squibb & Sons, L.l.c. | $479 |
|---|
| Travel and Lodging | $479 |
|---|
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| E.r. Squibb & Sons, L.l.c. Sep 24, 2025 | Travel and Lodging travel to Barcelona, Spain · in-kind | $479 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $50,150 in research payments for these studies, mostly to the institutions running them.
- A Phase 2, Open-label, Randomized Trial to Evaluate Two Dosing Regimens of Subcutaneous Formulation of Nivolumab in Combination with Intravenous Ipilimumab and Chemotherapy in Participants with Previously Untreated Me…
E.r. Squibb & Sons, L.l.c. - A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Tarlatamab Therapy in Subjects With Limited-Stage Small-Cell Lung Cancer (LS-SCLC) Who Have Not Progressed Following Concurrent Chemoradiat…
Amgen Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.